These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 178006)

  • 1. Striatal monoamines and reserpine and chlorpromazine rigidity.
    Jurna I
    Pharmacol Ther B; 1976; 2(1):113-28. PubMed ID: 178006
    [No Abstract]   [Full Text] [Related]  

  • 2. The cholinergic rigidity.
    Jurna I
    Pharmacol Ther B; 1976; 2(2):413-21. PubMed ID: 785492
    [No Abstract]   [Full Text] [Related]  

  • 3. Drugs affecting monoamines in the basal ganglia.
    Bartholini G; Pletscher A
    Adv Biochem Psychopharmacol; 1972; 6():135-48. PubMed ID: 4560163
    [No Abstract]   [Full Text] [Related]  

  • 4. The neuroleptics. 2. Neurophysiology and neuropharmacology.
    Albe-Fessard D; Bradley PB; Gerschenfeld HM; Herz A; Krnjević K; Lodin Z; Marczynski TJ; Massion J; Meulders M; Poirier LJ; Salmoiraghi GC; Schlag J; Tauc L; Wall PD
    Mod Probl Pharmacopsychiatry; 1970; 5():12-22. PubMed ID: 4348144
    [No Abstract]   [Full Text] [Related]  

  • 5. Striatal adenylate cyclase activity following reserpine and chronic chlorpromazine administration in rats.
    Rotrosen J; Friedman E; Gershon S
    Life Sci; 1975 Aug; 17(4):563-8. PubMed ID: 171534
    [No Abstract]   [Full Text] [Related]  

  • 6. Locomotor activity and speed of movements in relation to monoamine-acting drugs.
    Hassler R; Wagner A
    Int J Neurol; 1975; 10(1-4):80-97. PubMed ID: 126971
    [No Abstract]   [Full Text] [Related]  

  • 7. Dopaminergic inhibition of striatal cholinergic neurons: synergistic blocking action of gamma-butyrolactone and neuroleptic drugs.
    Stadler H; Lloyd KG; Bartholini G
    Naunyn Schmiedebergs Arch Pharmacol; 1974; 283(2):129-34. PubMed ID: 4369933
    [No Abstract]   [Full Text] [Related]  

  • 8. Injection of 6-hydroxydopamine and hydrogen peroxide into the substantia nigra and lateral ventricle of the cat: specific and nonspecific effects on striatal biogenic amines.
    Stahl SM; Daniels AC; Derda D; Spehlmann R
    J Neurochem; 1975 Jan; 24(1):165-72. PubMed ID: 1110359
    [No Abstract]   [Full Text] [Related]  

  • 9. Pathological aspects on Parkinson's syndrome.
    Steg G
    Acta Neurol Scand Suppl; 1972; 51():139-50. PubMed ID: 4268105
    [No Abstract]   [Full Text] [Related]  

  • 10. [The role of dopamine in the physiology and pathology of the basal ganglia].
    Arushanian EB
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1972; 72(4):595-603. PubMed ID: 4341763
    [No Abstract]   [Full Text] [Related]  

  • 11. Increase of striatal dopamine turnover by drugs: interference with granular storage or receptor blackade?
    Saner A; Pletscher A
    Eur J Pharmacol; 1977 Mar; 42(2):155-60. PubMed ID: 844496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lesions of the nigro-striatal dopamine pathway: effects on the storage and metabolism of striatal dopamine.
    Goldstein M; Ceasar P; Anagnoste B
    Pharmacol Ther B; 1976; 2(1):89-95. PubMed ID: 131326
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of neuroleptics on striatal dopamine synthesized from 14C-tyrosine.
    Nyback H; Sedvall G
    Pharmacol Ther B; 1976; 2(1):49-63. PubMed ID: 772722
    [No Abstract]   [Full Text] [Related]  

  • 14. Neuroleptics: relation between cataleptic and anti-turning actions, and role of the cholinergic system.
    Muller P; Seeman P
    J Pharm Pharmacol; 1974 Dec; 26(12):981-4. PubMed ID: 4156868
    [No Abstract]   [Full Text] [Related]  

  • 15. [Theories on the models of action of antipsychotic drugs].
    Carlsson A
    Tidsskr Nor Laegeforen; 1973 Jun; 93(17):1298-300. PubMed ID: 4356435
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparison of the acute actions of amine-depleting drugs and dopamine receptor antagonists on dopamine function in the brain in rats.
    Hong M; Jenner P; Marsden CD
    Neuropharmacology; 1987; 26(2-3):237-45. PubMed ID: 2884588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decrease in rat striatal acetylcholine levels by some direct- and indirect-acting dopaminergic antagonists.
    Consolo S; Ladinsky H; Bianchi S
    Eur J Pharmacol; 1975; 33(2):345-51. PubMed ID: 1183479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of continuous administration for 12 months of amine-depleting drugs and chlorpromazine on striatal dopamine function in the rat.
    Hong M; Kilpatrick GJ; Jenner P; Marsden CD
    Neuropharmacology; 1987 Aug; 26(8):1061-9. PubMed ID: 2889161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role of the polysynaptic system of substantia nigra in the cholinergic-dopaminergic equilibrium in the central nervous system.
    Wolfarth S; Dulska E; Gołembiowska-Nikitin K; Vetulani J
    Naunyn Schmiedebergs Arch Pharmacol; 1978 Apr; 302(2):123-31. PubMed ID: 652058
    [No Abstract]   [Full Text] [Related]  

  • 20. Reserpine-induced rigidity in rats: drug effects on muscle tone from corpus striatum and nucleus accumbens.
    Johnels B
    Pharmacol Biochem Behav; 1983 Sep; 19(3):463-70. PubMed ID: 6605540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.